Conbercept combined with 577 nm subthreshold micropulse laser for diabetic macular edema [PDF]
International Journal of OphthalmologyAIM: To evaluate the efficacy and safety of conbercept combined with 577 nm subthreshold micropulse laser (STML) for treatment of diabetic macular edema (DME). METHODS: A retrospective study was conducted.
Ying Han +7 more
doaj +2 more sources
Recent advances in the study of Conbercept for diabetic macular edema [PDF]
International Journal of Retina and VitreousDiabetic macular edema (DME) is one of the leading causes of blindness in diabetic retinopathy. As a domestically developed fusion protein drug in China, the anti-vascular endothelial growth factor (VEGF) agent Conbercept has demonstrated significant ...
Zhe Liu, Xin Zheng, Hong Li
doaj +2 more sources
Scientific ReportsThis study compares the effectiveness of Conbercept and Aflibercept in treating neovascular age-related macular degeneration (nAMD). Conducted at the First Affiliated Hospital of Chongqing Medical University's Ophthalmology Department (May 2020–May 2023),
Xing Wang, Hui Peng
exaly +2 more sources
Comparative Study on the Efficacy of Intravitreal and Subconjunctival Simultaneous Injection of Conbercept Followed by Trabeculectomy Versus Intravitreal Injection of Conbercept Followed by Trabeculectomy Combined With 5-Fluorouracil (5-FU) in the Treatment of Neovascular Glaucoma (NVG). [PDF]
J OphthalmolPurpose To compare the efficacy of trabeculectomy preceded by simultaneous intravitreal and subconjunctival conbercept administration with that of trabeculectomy combined with 5‐fluorouracil (5‐FU) following intravitreal conbercept injection in patients with neovascular glaucoma (NVG).
Xing P +7 more
europepmc +2 more sources
Frontiers in Pharmacology, 2021 Intravitreal injections of anti-vascular endothelial growth factor (VEGF) have become increasingly popular in the treatment of ocular diseases. However, few studies have determined the efficiency of unilateral intravitreal anti-VEGF injection in the ...
Yu Di, Haiyan Xu, Junjie Ye, Zijian Guo
doaj +1 more source
Proteomic analysis of anti-angiogenic effects by conbercept in the mice with oxygen induced retinopathy [PDF]
International Journal of Ophthalmology, 2020 AIM: To analyze the retinal proteomes with and without conbercept treatments in mice with oxygen-induced retinopathy (OIR) and identify proteins involved in the molecular mechanisms mediated by conbercept.
Ji Jin +3 more
doaj +1 more source
Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo. [PDF]
PLoS ONE, 2013 VEGF family factors are known to be the principal stimulators of abnormal angiogenesis, which play a fundamental role in tumor and various ocular diseases. Inhibition of VEGF is widely applied in antiangiogenic therapy.
Qin Wang +6 more
doaj +1 more source
Systematic Reviews, 2021 Background The comparative safety and efficacy between anti-vascular endothelial growth factor agents (anti-VEGFs) and between combined therapies for patients with neovascular age-related macular degeneration (nAMD) is unclear.
Andrea C. Tricco +17 more
doaj +1 more source
Frontiers in Medicine, 2022 PurposeTo investigate the intravitreal injection of conbercept as a treatment strategy for proliferative diabetic retinopathy (PDR) with or without center-involved diabetic macular edema (CI-DME) and evaluate its effect on the microvascular changes in ...
Wei Lin +25 more
doaj +1 more source
Anti-scarring effects of conbercept on human Tenon’s fibroblasts: comparisons with bevacizumab
BMC Ophthalmology, 2023 Background Safely inhibiting the formation of scar in the glaucoma filtration surgery (GFS) has always been an issue for clinical glaucoma doctors. Anti-vascular endothelial growth factor (VEGF) agents can reduce angiogenesis, and anti-placental growth ...
Lei Zuo +3 more
doaj +1 more source